Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2026-01-05 Sale | 2026-01-07 4:05 pm | Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO | 34,146 | $9.21 | $314,485 | 1,071,754 (Indirect Direct) | View |
| 2026-01-05 Sale | 2026-01-07 4:05 pm | Intellia Therapeutics Inc. | NTLA | Schultes Birgit C EVP, Chief Scientific Officer | 8,508 | $9.21 | $78,359 | 98,533 (Direct) | View |
| 2026-01-05 Sale | 2026-01-07 4:05 pm | Intellia Therapeutics Inc. | NTLA | BASTA JAMES EVP, General Counsel | 10,397 | $9.21 | $95,756 | 101,528 (Direct) | View |
| 2026-01-05 Purchase | 2026-01-07 4:05 pm | Intellia Therapeutics Inc. | NTLA | Cohen Fred E Director | 150,000 | $9.35 | $1,402,500 | 207,453 (Direct) | View |
| 2026-01-05 Sale | 2026-01-07 4:04 pm | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 11,903 | $9.21 | $109,627 | 121,249 (Direct) | View |
| 2026-01-05 Sale | 2026-01-07 4:03 pm | Intellia Therapeutics Inc. | NTLA | Clark Eliana EVP, Chief Technical Officer | 9,515 | $9.21 | $87,633 | 87,118 (Direct) | View |
| 2026-01-05 Sale | 2026-01-07 4:02 pm | Intellia Therapeutics Inc. | NTLA | Dulac Edward J III EVP, Chief Financial Officer | 6,379 | $9.21 | $58,751 | 99,683 (Direct) | View |
| 2026-01-05 Sale | 2026-01-07 4:01 pm | Intellia Therapeutics Inc. | NTLA | Dube Michael P VP, Chief Accounting Officer | 2,989 | $9.21 | $27,529 | 52,277 (Direct) | View |
| 2025-12-11 Sale | 2025-12-12 4:09 pm | Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO | 88,146 | $9.4886 | $836,384 | 1,114,457 (Indirect Direct) | View |
| 2025-10-01 Sale | 2025-10-03 5:13 pm | Intellia Therapeutics Inc. | NTLA | Schultes Birgit C EVP, Chief Scientific Officer | 31 | $17.38 | $539 | 105,184 (Direct) | View |
| 2025-10-01 Sale | 2025-10-03 5:13 pm | Intellia Therapeutics Inc. | NTLA | Dube Michael P VP, Chief Accounting Officer | 1,871 | $17.38 | $32,518 | 55,266 (Direct) | View |
| 2025-08-20 Purchase | 2025-08-22 4:30 pm | Intellia Therapeutics Inc. | NTLA | CHASE WILLIAM J Director | 100,000 | $10.03 | $1,003,000 | 134,693 (Direct) | View |
| 2025-07-23 Sale | 2025-07-25 4:05 pm | Intellia Therapeutics Inc. | NTLA | Dulac Edward J III EVP, Chief Financial Officer | 7,462 | $14.02 | $104,617 | 106,062 (Direct) | View |
| 2025-07-01 Sale | 2025-07-03 4:11 pm | Intellia Therapeutics Inc. | NTLA | Clark Eliana EVP, Chief Technical Officer | 1,022 | $9.82 | $10,036 | 95,369 (Direct) | View |
| 2025-07-02 Sale | 2025-07-03 4:07 pm | Intellia Therapeutics Inc. | NTLA | Dube Michael P VP, Chief Accounting Officer | 2,503 | $9.95 | $24,905 | 57,137 (Direct) | View |
| 2025-06-30 Sale | 2025-07-02 5:50 pm | Intellia Therapeutics Inc. | NTLA | GOODMAN JESSE Director | 3,094 | $9.395 | $29,068 | 24,359 (Direct) | View |
| 2025-04-29 Sale | 2025-05-01 4:24 pm | Intellia Therapeutics Inc. | NTLA | Bhanji Muna Director | 265 | $8.5 | $2,253 | 19,203 (Direct) | View |
| 2025-03-04 Sale | 2025-03-04 4:43 pm | Intellia Therapeutics Inc. | NTLA | Clark Eliana EVP, Chief Technical Officer | 679 | $8.99 | $6,104 | 141,083 (Direct) | View |
| 2025-03-04 Sale | 2025-03-04 4:21 pm | Intellia Therapeutics Inc. | NTLA | BASTA JAMES EVP, General Counsel | 2,572 | $8.99 | $23,122 | 169,068 (Direct) | View |
| 2025-01-29 Sale | 2025-01-31 4:17 pm | Intellia Therapeutics Inc. | NTLA | Bhanji Muna Director | 265 | $9.97 | $2,642 | 19,468 (Direct) | View |
| 2025-01-03 Sale | 2025-01-07 5:23 pm | Intellia Therapeutics Inc. | NTLA | Dube Michael P VP, Chief Accounting Officer | 1,372 | $12.18 | $16,711 | 45,640 (Direct) | View |
| 2025-01-03 Sale | 2025-01-07 5:22 pm | Intellia Therapeutics Inc. | NTLA | BASTA JAMES EVP, General Counsel | 7,074 | $12.18 | $86,161 | 74,497 (Direct) | View |
| 2025-01-03 Sale | 2025-01-07 5:20 pm | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 9,557 | $12.18 | $116,404 | 87,666 (Direct) | View |
| 2025-01-03 Sale | 2025-01-07 5:20 pm | Intellia Therapeutics Inc. | NTLA | Hicks Derek EVP, Chief Business Officer | 6,502 | $12.18 | $79,194 | 59,878 (Direct) | View |
| 2025-01-03 Sale | 2025-01-07 5:19 pm | Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO | 26,807 | $12.18 | $326,509 | 999,530 (Indirect Direct) | View |
| 2025-01-03 Sale | 2025-01-07 5:16 pm | Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | 8,966 | $12.18 | $109,206 | 77,388 (Direct) | View |
| 2025-01-02 Sale | 2025-01-06 4:16 pm | Intellia Therapeutics Inc. | NTLA | Clark Eliana EVP, Chief Technical Officer | 7,978 | $12.17 | $97,089 | 64,048 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2025-12-11 Exercise | 2025-12-12 4:09 pm | N/A N/A | Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO | 58,516 | $6.83 | 1,114,457 (Direct) | View |
| 2025-12-11 Exercise | 2025-12-12 4:09 pm | N/A 2026-02-03 | Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO | 58,516 | $0 | 1,114,457 (Direct) | View |
| 2025-06-11 Option Award | 2025-06-18 4:07 pm | N/A 2035-06-10 | Intellia Therapeutics Inc. | NTLA | Keresty Georgia Director | 19,450 | $0 | 43,333 (Direct) | View |
| 2025-06-11 Option Award | 2025-06-13 4:36 pm | N/A 2035-06-10 | Intellia Therapeutics Inc. | NTLA | Verwiel Frank Director | 19,450 | $0 | 37,398 (Direct) | View |
| 2025-06-11 Option Award | 2025-06-13 4:33 pm | N/A 2035-06-10 | Intellia Therapeutics Inc. | NTLA | GOODMAN JESSE Director | 19,450 | $0 | 38,903 (Direct) | View |
| 2025-06-11 Option Award | 2025-06-13 4:30 pm | N/A 2035-06-10 | Intellia Therapeutics Inc. | NTLA | Goff Brian Director | 19,450 | $0 | 34,859 (Direct) | View |
| 2025-06-11 Option Award | 2025-06-13 4:27 pm | N/A 2035-06-10 | Intellia Therapeutics Inc. | NTLA | Bhanji Muna Director | 19,450 | $0 | 38,653 (Direct) | View |
| 2025-06-11 Option Award | 2025-06-13 4:25 pm | N/A 2035-06-10 | Intellia Therapeutics Inc. | NTLA | CHASE WILLIAM J Director | 19,450 | $0 | 46,143 (Direct) | View |
| 2025-06-11 Option Award | 2025-06-13 4:23 pm | N/A 2035-06-10 | Intellia Therapeutics Inc. | NTLA | Cohen Fred E Director | 19,450 | $0 | 68,903 (Direct) | View |
| 2025-03-01 Option Award | 2025-03-04 4:43 pm | N/A 2035-02-28 | Intellia Therapeutics Inc. | NTLA | Clark Eliana EVP, Chief Technical Officer | 77,714 | $0 | 141,083 (Direct) | View |
| 2025-03-01 Option Award | 2025-03-04 4:41 pm | N/A 2035-02-28 | Intellia Therapeutics Inc. | NTLA | LEONARD JOHN M President and CEO | 332,000 | $0 | 1,331,530 (Direct) | View |
| 2025-03-01 Option Award | 2025-03-04 4:34 pm | N/A 2035-02-28 | Intellia Therapeutics Inc. | NTLA | Dulac Edward J III EVP, Chief Financial Officer | 114,629 | $0 | 180,953 (Direct) | View |
| 2025-03-01 Option Award | 2025-03-04 4:28 pm | N/A N/A | Intellia Therapeutics Inc. | NTLA | Dube Michael P VP, Chief Accounting Officer | 14,000 | $0 | 59,640 (Direct) | View |
| 2025-03-01 Option Award | 2025-03-04 4:26 pm | N/A 2035-02-28 | Intellia Therapeutics Inc. | NTLA | Lebwohl David EVP, Chief Medical Officer | 104,914 | $0 | 192,580 (Direct) | View |
| 2025-03-01 Option Award | 2025-03-04 4:24 pm | N/A 2035-02-28 | Intellia Therapeutics Inc. | NTLA | Schultes Birgit C EVP, Chief Scientific Officer | 91,314 | $0 | 158,929 (Direct) | View |
| 2025-03-01 Option Award | 2025-03-04 4:21 pm | N/A 2035-02-28 | Intellia Therapeutics Inc. | NTLA | BASTA JAMES EVP, General Counsel | 97,143 | $0 | 169,068 (Direct) | View |
Ownership | 2025-01-23 5:41 pm | N/A N/A | Intellia Therapeutics Inc. | NTLA | Schultes Birgit C EVP, Chief Scientific Officer | 0 | $0 | 249,121 (Direct) | View |